SecBot SecBot
SECBOTREPLAY Home › Report › CPRX

CPRX · Catalyst Pharmaceuticals announced topline results from a Phase 1 study…

CATALYST PHARMACEUTICALS, INC. · 8-K filed Jun 30, 2026 at 16:57 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Jun 30, 2026 at 16:57 ET

Catalyst Pharmaceuticals announced topline results from a Phase 1 study of vamorolone (AGAMREE) showing balanced corticosteroid activity with glucocorticoid effects but without significant immunosuppression at clinical doses. The data support the drug's current DMD dosing and potential expansion into other chronic inflammatory rare diseases, though no near-term regulatory or financial impact is expected.

  • Phase 1 study in healthy adults showed vamorolone and deflazacort had comparable cortisol suppression at clinical doses.
  • Vamorolone demonstrated less pronounced immunosuppressive biomarker effects than deflazacort in Part A.
  • In Part B, clinically relevant immunosuppression was observed only at the highest dose (40 mg/kg/day), which is above approved dosing.
  • No relevant immunosuppressive effects were seen at lower doses (9 or 27 mg/kg/day).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access